News / Press Release

If I Enter a Cancer Clinical Trial, Is There a Chance I will Receive a Placebo Instead of Cancer Therapy?

January 13, 2017

Only when a cancer clinical trial involves people with treatment-resistant or progressive cancer would a placebo be given.  Participants are always informed they may receive a placebo prior to the start of the trial and have the option of leaving the trial if they do not wish to continue. 

Double-blind controlled studies incorporating a placebo group do so to “blind” physicians and subjects to the kind of the treatment received. In other words, only the researchers know who is taking a placebo. This avoids bias when measuring results of the study, especially results provided by doctors examining participants.

Informed Consent and Placebos in Cancer Clinical Trials

An informed consent document tells trial participants they may receive a placebo during the course of the experimental treatment. Even patients undergoing standard cancer treatments will be asked to sign a consent form explaining risks associated with a certain surgery or procedure. Signing a consent form means the person has agreed to undergo the treatment and understands risks or implications involved with the treatment.

If clinical trial participants are not permitted to sign an informed consent document regarding the use of placebos in a trial and find out they were given placebos, the institution performing the trial could be sued by the participants for unethical practices. In addition, the FDA and other regulatory organizations could revoke the institution’s ability to perform any further trials involving experimental therapies.

Problems With Placebos in Cancer Trials

Research into the placebo effect is ongoing and has yet to provide empirical of physiological mechanisms supporting its efficacy. Another problem with using placebos in any trial is called the “wellness effect”, or the ability of certain health problems to improve without treatment. This may be due to people taking better care of themselves because they think they will get better or because of the beneficial effects of enhanced mood and general well-being.

Some researchers think placebos may actually facilitate remembering a time before symptoms of a disease emerged and the person began feeling sick. Neurologists call this theory remembered wellness and suspect a combination of the placebo effect and remembered wellness may incite beneficial chemical changes in the brain to reverse certain medical conditions.

If done properly, a placebo-controlled, cancer clinical trial can provide significantly statistical evidence that a new cancer treatment holds promise. Alternately, placebos used improperly may provide erroneous evidence that inadvertently allows marketing of a new, possibly harmful drug.  

If you would like more information about the use of placebos in cancer clinical trials, please contact us today.

About Translational Drug Development (TD2)

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

About TD2

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

Contact
Tara Franks
602-358-8322
Get free tips, tools and resources by subscribing to the TD2 Newsletter: